Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04635189 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 1 month later Jul 31, 2026 → Sep 8, 2027
See other at-risk trials from University of Rochester

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jul 31, 2026 to Sep 8, 2027
    • Eligibility criteria expanded, about 19 words
  2. Primary and study completion dates: Jul 31, 2025 to Jul 31, 2026v9
  3. Primary and study completion dates: Jul 31, 2024 to Jul 31, 2025
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v8
  4. Primary and study completion dates: Jul 31, 2023 to Jul 31, 2024v7
  5. Primary and study completion dates: Jul 31, 2022 to Jul 31, 2023v6
Show 4 earlier versionsHide 4 earlier versions
  1. Start date: Jul 1, 2021 to Jul 27, 2021v5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 2021 to Jul 1, 2021
    v4
  3. Start date: Feb 2021 to Jun 2021v3
  4. Start date: Dec 1, 2020 to Feb 2021v2 Show 5 more changesShow less
    • Interventions: Daratumumab and Lenalidomide (Drug) to Daratumumab (Drug), Dexamethasone (Drug), Lenalidomide (Drug)
    • Study title shortened, about 8 words
    • Study arms: 1 to 3
    • Eligibility criteria expanded, about 3 words
    • Study description expanded, about 1 word
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine the effects of daratumumab and lenalidomide without steroids for treating patients with multiple myeloma.
Trial Details
NCT Number NCT04635189
Lead Sponsor University of Rochester
Conditions
(from sponsor)		 Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov